High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.
暂无分享,去创建一个
[1] S. Withers,et al. Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. , 2006, Journal of molecular biology.
[2] Chi‐Huey Wong,et al. Novel Five‐Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis , 2006, Chembiochem : a European journal of chemical biology.
[3] P. Deen,et al. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. , 2005, Molecular biology of the cell.
[4] Klaus-Peter Zimmer,et al. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. , 2005, Chemistry & biology.
[5] A. Ciechanover. Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture). , 2005, Angewandte Chemie.
[6] Matthew S Macauley,et al. O-GlcNAcase Uses Substrate-assisted Catalysis , 2005, Journal of Biological Chemistry.
[7] D. Remick,et al. Mechanisms of Dimethyl Sulfoxide Augmentation of IL-1β Production 1 , 2005, The Journal of Immunology.
[8] J. Roth,et al. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] D. Bichet,et al. Pharmacological chaperone action on G-protein-coupled receptors. , 2004, Current opinion in pharmacology.
[10] Eric D. Brown,et al. High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase , 2004, Chemistry & Biology.
[11] S. Brothers,et al. Pharmacologic Rescue of Conformationally‐Defective Proteins: Implications for the Treatment of Human Disease , 2004, Traffic.
[12] Chi‐Huey Wong,et al. Synthesis and high-throughput screening of N-acetyl-beta-hexosaminidase inhibitor libraries targeting osteoarthritis. , 2004, The Journal of organic chemistry.
[13] Michel Bouvier,et al. Pharmacological chaperones: potential treatment for conformational diseases , 2004, Trends in Endocrinology & Metabolism.
[14] S. Withers,et al. Pharmacological Enhancement of β-Hexosaminidase Activity in Fibroblasts from Adult Tay-Sachs and Sandhoff Patients* , 2004, Journal of Biological Chemistry.
[15] C. Wermuth. Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.
[16] Seiichiro Ogawa,et al. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] Eric D. Brown,et al. High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate. , 2003, Bioorganic & medicinal chemistry letters.
[18] Jian‐Qiang Fan. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. , 2003, Trends in pharmacological sciences.
[19] Timm Maier,et al. The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease. , 2003, Journal of molecular biology.
[20] M. James,et al. Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. , 2003, Journal of molecular biology.
[21] M. Piccart,et al. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours. , 2003, European journal of cancer.
[22] Ernest Beutler,et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] D. Scudiero,et al. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. , 2002, Current topics in medicinal chemistry.
[24] A. Fersht,et al. A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. Ramos,et al. Naphthalimides as Anticancer Agents: Synthesis and Biological Activity , 2001 .
[26] S. Withers,et al. Crystallographic Evidence for Substrate-assisted Catalysis in a Bacterial β-Hexosaminidase* , 2001, The Journal of Biological Chemistry.
[27] C. Scriver,et al. The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.
[28] D. V. Von Hoff,et al. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Ishii,et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. , 2000, European journal of biochemistry.
[30] M. Mayersohn,et al. Evaluation of a minimal experimental design for determination of enzyme kinetic parameters and inhibition mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.
[31] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[32] K. Mills,et al. Application of magnetic chromatography to the isolation of lysosomes from fibroblasts of patients with lysosomal storage disorders , 1998, FEBS letters.
[33] D. Mahuran,et al. A Pro504 → Ser Substitution in the β-Subunit of β-Hexosaminidase A Inhibits α-Subunit Hydrolysis of GM2Ganglioside, Resulting in Chronic Sandhoff Disease* , 1998, The Journal of Biological Chemistry.
[34] B Henrissat,et al. Structural and sequence-based classification of glycoside hydrolases. , 1997, Current opinion in structural biology.
[35] S. Withers,et al. NAG-thiazoline, An N-Acetyl-β-hexosaminidase Inhibitor That Implicates Acetamido Participation , 1996 .
[36] R. Vincentelli,et al. N-Acetylglucosaminidase (chitobiase) from Serratia marcescens: gene sequence, and protein production and purification in Escherichia coli. , 1996, Gene.
[37] D. Mahuran,et al. Direct determination of the substrate specificity of the alpha-active site in heterodimeric beta-hexosaminidase A. , 1996, Biochemistry.
[38] Zbigniew Dauter,et al. Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay–Sachs disease , 1996, Nature Structural Biology.
[39] J. Castellano,et al. Bis-naphthalimides: a new class of antitumor agents. , 1993, Anti-cancer drug design.
[40] D. Mahuran,et al. beta-Hexosaminidase isozymes from cells cotransfected with alpha and beta cDNA constructs: analysis of the alpha-subunit missense mutation associated with the adult form of Tay-Sachs disease. , 1993, American journal of human genetics.
[41] T. Burnakis,et al. Aldose Reductase Inhibitors: An Update , 1993, The Annals of pharmacotherapy.
[42] D. Mahuran,et al. The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis. , 1991, Biochimica et biophysica acta.
[43] D. Mahuran,et al. Translation initiation in the HEXB gene encoding the beta-subunit of human beta-hexosaminidase. , 1990, The Journal of biological chemistry.
[44] G. Legler,et al. Synthesis and Inhibitory Properties of 2-Acetamido-2-Deoxynojirimycin (2-Acetamido-5-amino-2,5-dideoxy- D -glucopyranose, 1) and 2-Acetamido-1,2-dideoxynojirimycin (2-Acetamido-1,5-imino-1,2,5-trideoxy- D -Glucitol, 2) , 1989 .
[45] J. Bayleran,et al. Tay-Sachs disease with hexosaminidase A: characterization of the defective enzyme in two patients. , 1987, American journal of human genetics.
[46] R. Massarelli,et al. Enzymes of Lipid Metabolism II , 1986, NATO ASI Series.
[47] D. Hutcheon,et al. A Decade of Developments in Diuretic Drug Therapy , 1986, Journal of clinical pharmacology.
[48] R. Proia,et al. Faulty association of alpha- and beta-subunits in some forms of beta-hexosaminidase A deficiency. , 1984, The Journal of biological chemistry.
[49] A. Hasilik,et al. Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. , 1980, The Journal of biological chemistry.
[50] A. Hasilik,et al. Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues. , 1980, The Journal of biological chemistry.
[51] V. A. Kul'shin,et al. A continuous fluorimetric assay for glycosidase activity: human N-acetyl-beta-D-hexosaminidase. , 1980, Analytical biochemistry.
[52] J. Callahan,et al. G M1 -gangliosidosis (Type II): studies on a fibroblast cell strain. , 1970, Biochemical medicine.
[53] G. Charria-Ortiz. The GM2 Gangliosidoses , 2007 .
[54] Kai Du,et al. The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.
[55] D. Remick,et al. Mechanisms of dimethyl sulfoxide augmentation of IL-1 beta production. , 2005, Journal of immunology.
[56] A. Vasella,et al. Glycosidase mechanisms. , 2002, Current opinion in chemical biology.
[57] Kuldeep,et al. Translation Initiation in the HEXB Gene Encoding the & Subunit of Human , & Hexosaminidase , 2001 .
[58] Elizabeth F. Neufelds,et al. Faulty Association of CY-and @-Subunits in Some Forms of @-Hexosaminidase A Deficiency , 2001 .
[59] M. Braña,et al. Naphthalimides as anti-cancer agents: synthesis and biological activity. , 2001, Current medicinal chemistry. Anti-cancer agents.
[60] Satoshi Ishii,et al. Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.
[61] K. Sandhoff,et al. Biochemical basis of late-onset neurolipidoses. , 1991, Developmental neuroscience.
[62] H. Willard,et al. Molecular Heterogeneity in O-Variant GM2 Gangliosidosis , 1986 .